Endobronchial Manifestation of Methotrexate-induced Lymphoproliferative Disorder

Lymphoproliferative disorders can occur in patients with autoimmune disorders who undergo long-term methotrexate therapy (MTX-LPD). Although the manifestations of MTX-LPD are diverse, little attention is paid to endobronchial involvement. We herein describe two patients with MTX-LPD who presented wi...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2019/06/01, Vol.58(11), pp.1597-1603
Main Authors: Ikeue, Tatsuyoshi, Kawachi, Hiroaki, Yoshida, Hiroshi, Tanaka, Eiichiro, Noguchi, Susumu, Fukao, Akari, Terashita, Satoshi, Tajiri, Tomoko, Horikawa, Sadao, Sugita, Takakazu
Format: Article
Language:English
Subjects:
Autoimmune diseases
Case Report
endobronchial involvement
Immunoproliferative diseases
Internal medicine
Lesions
Lymphocytes
lymphomatoid granulomatosis
Methotrexate
methotrexate-induced lymphoproliferative disorder
Mucosa
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphoproliferative disorders can occur in patients with autoimmune disorders who undergo long-term methotrexate therapy (MTX-LPD). Although the manifestations of MTX-LPD are diverse, little attention is paid to endobronchial involvement. We herein describe two patients with MTX-LPD who presented with parenchymal pulmonary tumors and endobronchial involvement of LPD; one had lymphomatoid gramulomatosis and the other LPD. The patients had no tumors adjacent to the endobronchial lesions. The endobronchial findings included multiple protruded mucosal lesions covered with white material, which was pathologically consistent with LPD. Recognition of the findings may help in making an earlier diagnosis of MTX-LPD in appropriate settings.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2109-18